### Why was this study done?

This study was done to evaluate the efficacy and safety of secukinumab in pediatric patients aged 6 to 18 years with severe chronic plaque psoriasis over one year.

### What did this study look at?

The study compared the effectiveness of secukinumab (75-150 mg) and etanercept in improving psoriasis severity and quality of life among patients with severe plaque psoriasis.

### Design of the study

Patients were randomized into three treatment groups:
- Secukinumab 75-150 mg (9/10 patients)
- Secukinumab 150-300 mg (5/10 patients)
- Placebo (2/10 patients)

### What were the results?

The results showed that secukinumab had a significantly greater effect on psoriasis in children than placebo. The majority of pediatric and adolescent patients said their psoriasis symptoms had little or no impact on their quality of life with secukinumab treatment over 1 year.

### Why does this matter?

Psoriasis can have a profound physical and psychological impact on children, with limited options for effective treatment. This study provides important insights into the efficacy and safety of secukinumab in pediatric patients, helping to improve quality of life for those affected by psoriasis.

### References


---

**Psoriasis**

Psoriasis is a long-term autoimmune disease that features red/purple patches of skin. These “plaques” that are covered by silvery or white scales. These can be raised, red or purple patches covered with silver or white scales. These can affect other parts of the body, for example it can cause joint disease.

**Psoriasis Area Severity Index (PASI):**

Psoriasis Area Severity Index (PASI) is a commonly used measure to assess the extent and severity of psoriasis. It takes into account the area of skin affected, as well as the severity of redness, thickening, and scaling.

**Quality of life:**

Quality of life is significantly impacted by psoriasis, both physically and emotionally. It can negatively affect daily activities, self-esteem, and overall well-being.

**Children’s Dermatology Life Quality Index (CDLQI):**

Children’s Dermatology Life Quality Index is a questionnaire used to assess the impact of psoriasis on children’s quality of life. It includes 10 items related to skin condition, physical and social functioning, and psychological burden.